The approval paves the way for the company to raise growth capital from its existing shareholders, further strengthening its financial foundation and supporting its strategic initiatives
Remedium Lifecare, a fast-growing manufacturer of pharmaceutical intermediates and speciality chemicals, has received approval from the Bombay Stock Exchange (BSE) for its proposed rights issue.
The approval paves the way for the company to raise growth capital from its existing shareholders, further strengthening its financial foundation and supporting its strategic initiatives, including manufacturing expansion, product development, and global market penetration.
Key Highlights of the Rights Issue (as approved):
• Record Date: Tuesday, April 15, 2025
• Issue Size: Rs 4,919.04 lakhs (Assuming Full Subscription)
• Price per Share: Rs 1.00 per Equity Share
• Total Number of Shares: 49,19,04,000 fully paid-up equity shares of face value Rs 1/- each
• Rights Ratio: 61 Rights Equity Shares for every 50 fully paid-up equity shares held as on the Record Date
• Instrument: Fully paid-up equity shares having a face value of Rs 1 each
• Purpose: Working capital Requirements, Equipment for R&D and expansion
“This approval from the BSE marks a significant milestone in our journey. We remain committed to enhancing shareholder value while scaling up our operations responsibly and sustainably,” said Adarsh Munjal, Whole Time Director, Remedium Lifecare.
The rights issue comes when Remedium Lifecare is gaining strong traction in international markets. In February 2025, the company secured a multi-year export contract worth Rs 182.7 crore with a leading UK-based pharmaceutical distributor. The company is well-positioned to capitalise on rising global demand in key therapeutic segments such as anti-infectives, cardiovascular, CNS, and oncology-supportive drugs.
